Coronary patency after intravenous infusion of recombinant tissue-type plasminogen activator in acute myocardial infarction  by Brower, Ronald W et al.
With the recent completion of the firs, rbree European ,rl~l~ 
(l-3) on recombinant tissue-type plasmmogen ac,~a,or lit- 
PA). which investigated safety and ellicacy in patients wnh 
acute myocsrdiai infarction, a numxr of other prachcal 
issues remain to be examined. Farerr JT, among these 15 rbe 
identification of factors, accessible early m ,h; bospitabra- 
lion phase, that have a bearing on ,bc cuccess or Murc of 
rt-PA as a lhrombolytic agen,. Such nformadon could lead 
toamore specific se, of indicaions sod con,raiodica,ionr. a, 
well as extend our knowledge of the behavior of n-PA as ii 
thromboly:ic agent in the setting of auk myocardial mbrc. 
lion (for example. the relation belwern baseline cliwal dam 
and vessel pa,ency, use of vasodilaw~ and clec,rocardm- 
graphic (ECG) evidencr uf mfarc, bution and sue have 
obvious significance). The delay from orxe, of symptomx CO 
Lberapy is a crirical factor in salragq jeopardized myocar- 
chum. but does this delay aLo have a hexing on ,he ca:ncily 
of r,-P4 lo dirsolve ;hrombi? Finally. in ,he Europeao trials 
t l-31. the resull~ of hemoatic laboratory ,es,s and renal nnd 
hepatic enwx axwnen,s were examined hecaurc these 
may madlfy ihe nctiwy Ma-PA and can he assessed early 
durmg Ihc bo?pi,aliza,mn phase The dim of ,his rcpcn i, 10 
derermmc the cx,en, ,o which these fac,ors relale ,o angio- 
graph,c patency after tnfuston of R-PA. 
Protocol. ‘The results reponed hrrc arc based on tbrcc 
studin. Ihe core results of which have been described 1!-3). 
In ,he firu \,udy. recombinan, lisrue-tvw plasmimxen acti- 
vatoi (rt-PAI w.& compared wrh placebo I; FIX e&n vw,h 
a tu,ai rscrwtmen, of 129 oadenta. In ,he recond wdy. n-P.4 
WG compxcd with rlrepiokioae an xvcn ccmers. a1w wirh 
a toul recrumnent of I?9 parients. In the third study. I I 
center, paimpmd I” acaronary ~eocc,uwn wdy. ,  wh,ch 
a total of II1 pa,ien,s were evaluated. Although different 
orotocols wre used. the inclwion and erclwion criteria were 
Trial oxdication. lmmed~atcly after admission to the 
trial. ali palicnts rccewcd 5.0% 1” cf heparin. followed by 
an mtravenou~ mfusion oin-PA (g-l IOil. Gcnemcch Inc.). 
In the firs two trials. the dosage WB~ 0.75 mgiks body 
weight. up m a maximal dose 0160 mg infused intravenously 
over 90 mm. In fact. most patients received the full dose 
because body weight was usually >7S kg, In the third study. 
n-PA was administered as a; intravenous infwion of40 mg 
over %I mm The we oi orhe- medicalion was left to the 
discretion of the physician. although it was requested that 
vasodilators not be given during cardiac catherization unless 
the patient‘s condition required such therapy. 
Inclusionirxclusinn criteria. With one exception. the Figure 1. Flow diagram ofthe 381 palienlr entered into the first three 
same clinical inclusion and exclusion critetia lvere applied in Eumpe~n trials of recombwx~t tissue-type plarminogen activator 
all three studier (l-3). In the first two studies. paticna with M-PA). including the 241 patients in this report. IRV = infarct- 
a historv of a orevious mvocardial infarction were excluded. 
related vessel. 
In the ‘reocciuion study, a previous infarction did not 
automatically mean excIu+m. provided it was in a different 
cardiac area from that of the current event. 
7he follownp rrr?lure,ne,rrs had 10 hr fidfill~d nt odmir- 
rion: lithe inf&on’coald be started within b h of the acute 
event (4 h in the reoccluioo study): 21 at least two precordial 
leads showed s3 mm ST segment elevation. or at least two 
fmntal plane leads showed r! mm ST segment elevation; 3) 
patients with a systolic blood pressure ~90 mm Hg and a 
pulse rate >I 10 beaaimin and showing clinical signs of 
eardin~~nir shock ‘.‘crc eichdid. 
Addirkmol rrr,,~n’on rriruio i,x,,,ded age <?I or >70 yr. 
inability to gwe informed consent, prolonged or traumatic 
cardiac massage. requirement of a respirator. pregnancy or 
current menstruation. previous use of or known hypersensi- 
tivity to strsptokinase, receipt oioral anticoagulants. recent 
major trauma. known bleeding disorder, previous hean 
surgery. mr$ar noncardiac surgery wilhin 6 weeks. cerehm- 
vascular accident within 6 months. gastrointestinal or geni- 
tourinary bleeding within 3 months. major hepatic disease, 
major renal disease. proliferative diabetic retinopathy. csn- 
ccr alcohol or drug abuse. problems anticipated with fol- 
low-up and previous tnyocard~al mfarctian (In rhe reocclu- 
sion study, a previous infarct was allowed prowded it was in 
a diReren! area). 
Provided that these criteria were met. the patient was 
registered by telephone m the central allocation service. 
which assigned the allocated treatment. 
65 received streotakinase. 2 had less than the ful! dose rt-PA 
and 6 had un&essable angiograms). Thus. this report is 
based on 243 pntienta who received the prescribed dose of 
rt-PA and whose 90 min coronary angio&am was indepen- 
dently assessed as being either patent or occluded (Fig. I). 
Blood samples and enzynte a&sir. Blood samples were 
obtained within 30 min before infusion. Plasminogen and 
fibrinogen were assessed in the Central Coagulation Labo- 
ratory (1-3); other blood tests and enzyme a~sessroe”t* were 
performed locally. The values obtained io local hospitals 
were converted to comparable units at the data center, and 
expressed as a fraction of the upper limit for normal values 
based on reference data provided by the cooperating clinics. 
Data treated in this manner are indicated by an asterisk in 
the tables. 
Eleetmcardiogram. The admission electrocardiogram 
(ECG) was assessed locally and reported to the data center 
as follows: leads V, to V,, each coded for 23 mm ST 
segment elevation (coded as positive or negalive), and leads 
I. II. 111. aVR. AVL and AVF. each coded for 5 2 mm ST 
segment elcvalion (coded as positive or negative). This was 
recoded as four variables: I) anterior involvement, if two or 
more of leads V,. V?. V, or V, were Positive; 2) inferior 
involvement. if two or more of leads II, 111 and aVF were 
positive; 3) lateral involvement, if two or more of leads V,. 
V,. I and aVL were positive; 4) nonspe:cific localization, if 
none of the precedinc. 
TOI rhv ruhpmvp OJ pamm repurrrd km. nddi~iotrtd The extent of the ischemic area was computed on the basis 
srkwioa criruriu upplied. I) only those patients treated with of an assigned weighting factor of 3 for positive coding of 
a-PA in the three trials (I-3) were Included; 2) patients who leads V, to V, and a weighting factor of 2 for the other leads. 
did not receive rhe full dox of CPA are excluded; 3) divided by the numbcr of lcads recorded @w~lly I?). 
patiemr whuac coronary patency or occh.sinn at 90 min Coranar~ angiupraph>. The coronary aogiograms were 
could not be retrobpectively estabhshed by a review panel of a\ses\ed by an Independent review panei as previously 
indcpcndcnt experts because the films were unavailab!e or of described (l-3). In short. each angiogram was assessed by 
inullicient quality werr a150 excluded. two experienced cardiologists who were not informed of the 
Study patients. Of the 381 palicntb rccruitrd for ths trials. trcatmcnt or clinical history of the patient other than 
138 ucrc excluded from this analysis (65 rcceivcd placebo. whether or not the ECG al the time of entry showed ST 
segmenr e!evatlon m leads V,. V, and V; The caqe wa\ 
classified as occloded if dny vessel in ~tw m!:~:! related aen 
was ecored as B !o!Bl!y “C.._... FIIII1PII “.-WC, w,h C’T “,!,bo,,, 
collateral Row. or as a sobtotal occlwiw in which the vc\\el 
did not fill within three cardiac cycles. A ~tenow of NW 
for which the ves~cl filled within tbrce cardux cycles. but 
“of through collateral Row was clawfied 1s patem 
.Statil!LS. !n .?cSC:d^^F: .;.i:b :bi alill, ;s,Lr,‘bcd eilr,,er 
in this report, infarct-related vesse! patency rate rua~ 89. 
sessed in a number of subgroups. For measurements involv- 
ing numeric quantitie,. generally three subgroups were 
formed on the basir of a nearly equal number of meawe. 
meats in each subgroup unless the sample was too small or 
other grouping criteria were more nppropnate. The second 
and third subgmupr were compared wth the Bnt bobgroup 
(reference group) in the form of a rate ratio IR- patency rate 
in second or third subgroup divided by the patency rate m 
the first subgroup). The 95% confidence interva! for the rate 
ratio was determined as previously described 141. Multira- 
riate logistic regression analysis was performed on selectsd 
groups of variables uitb the B41DF ~at~blaal package 
(program MLR,. 
Results 
Ui the L43 patients satisfying the mclus~on critena. the 
median age was 56 yr (90% range 37 to V& 204 @I%) were 
men. The admission ECG indicated anterior involvement in 
126. infenor involvement in 95. lateral in~olwement in 57 and 
a nonspecific localization in 14. Three patients had both 
anterior and inferior involvement. 
Median syrrnlic hloodpresswe on udmisrm was 130 mm 
Hg (90% range IW to 180) and median diastolic prewre WBL 
80 mm Hg 190% range 60 to I IO). Pulmonary rates were 
detected in 49 cakes L’O%). 
Indep-ndear omnsmmr of r/w wmno~ un,q;ocram, 
resulted in the infarct.related vessel beingscored as patent in 
I59 cases and occluded in 84. The avcraee ~atencv rate was 
65% (95% confidence interval 59 to 7l%i. 
Ten patients died in the hospital (hoipttal mortality riltr 
4.1%). 
Interstudy variability. The results rcportcd hen: arc 
pooled from three studier involving rl-PA (Fig. I j. In Ihe 
study contrasting rt-PA with placebo. the patency rate with 
rt-PA WBF 61% (confidence inlerwl JR to 73%) while that in 
the Ftudy contrasting It-PA with strep,okinase was 69% 
(confidence interval 56 to 80%). Patency we in the n-PA 
reocclusioo study was 66% (confidence mterval X m 74%) 
The ditTerencr of*% between the two extreme YPIUCS 15 not 
statistically significant Patency WC m the reocclu~mn study 
was mtermediate between thurs OS the other two >tudic\ 
despite ils lower dosage of rt-PA. 
Eleclrorardlugram and clinical st;ltm at entry. A wn- 
may of the relation betwren the pat~rmy rate achieved after 
infuwn of &PA and the ~ta:us at entry (age. sex. ECG area 
of inwlrement. blood pressure on admissmn and presence 
of pulmonary rale5) is presettted m Table I. Although 
patrncy mte was slightly higher in the age group >6O yr. the 
confidence interal for the rate moo ,n relm,on I” the 
yoongcrt ap group did not exceed unity. The patency rate 
for men and women was also similar. 
Tire mqijori~y of pnrimrr 15/c/,) were elnssifed (1s Imini: 
~~n~~~rw o~wlvmcrr~: however. the difference !n patency 
rate bctwcrl anterior myxardial mfarctmn (64% patency1 
and inferior or lateral mfarction (66% paxncy) was mmlmal. 
“nly three paoents appeared 10 have 1111 three myocard,al 
rcgmnr mvolved m the mfarcrion. Infarct size. ar estimated 
from the ECG. c:howed a weak trend toward a lesrer 
lbkehhood of patency in association with larger infarct\. 
However the rate ratior were not \t&t!cally rigniftcantly 
ddferent (from unity! nordtd multivariate logrsttc regrewon 
anaiyvs whstamiate any trmd. 
Syrmlir hloodprersurr (~140 mm Hg) and an imemxdi- 
ate valw for hearr rate (from 70 lo 90 bcalslmin appeared to 
be associated wilh a less favorable ou~cornc, although this 
trend was less marked for diastolic blood pressure. How- 
ever. the confidence intervals of lhe rate ratios did not 
exceed wily m any subgroup. This ~8s also confirmed by 
multivariate logistic reprercion analysis. 
Pa,,,,on.rv role., were DrCce”! 1” 90lne dpnrw in xl% of 
p&m. kvirh no &a on patency rates. 
Medication before infusion of rt.PA. The use of sublineual 
or intravenous nitrates. calcium channel antagonists and 
beta-adrcncrgic blocking agents was xcordcd for the 6 h 
period before the sta.rl of infusion (Table 2). Use of such 
medication was ar the discredon of the responsible physi- 
cian. 
lnlravcnous nmales u’ere given in 12 palznta. and the 
patency rate was 9% higher in that group. The use of 
sublingual ndratcs. however. showed a much weaker I& 
lion to patency. Calcium channel anlagonists appeared to 
play a neutral role m relation to patency. Beta-blockers were 
admimslered in only seven patients. and the difference in 
patency rates for this small sample was not large enousb to 
attach unportance lo the difference. Multivatiale !ogislic 
regression analysis faded to identify any of these medica- 
lions as significantly affecting palency. 
&la) between a&et of syo&ms and start of the infusion. 
This vrar <2 h in 45 pauents, but 24 h in 36 palients (Fig. 
2Ai. The majority Li61 patients) wcrc treated within 2 to 4 h 
Fi~re 2. A. Histogram of the lime delay from the onset of symp 
tanns to the start of the rl-PA infusion in 243 phtients. Barn in 
increments of05 8. Patency rate for subgroups of padents treated 
wth rt-PA within 2 b, from 2 to 4 hand after4 h. Numben Watba 
bars indicate the number of patients. Numbers above tiw bars 
represent percent patency rate. 
of symptoms (Table 3). The difference in patency rate 
between the early and the late treatment zqoups was 1%. 
suggesting thal the earlier the infusion can be staled, the 
belter the patency rate (Fig. 28). However, the wide confi- 
dcncc io&ds ii the rate &ios prohibited any firm conclu- 
sions. a result that was confirmed with logistic regression 
analysis. 
Angiographic findings. Results concerniog whether the 
infarct-related vessel was proximal or dislal or involved the 
right. left anlerior descending VI circumflex coronary artery 
are reponed in Table 4 and Figure 3. The majority of 
infxct-related vessels (65%) were classified as proximal 
vessel dasease. Nevenheless, the patency rste difference of 
2% compared wi!b nonproxinal disease suggests that prox- 
imal vessel disease is not a pertinent factor in relation to the 
capacity of rl-PA as a thrombolytic agent. 
Hemwtaris. Although plasminogen determinatnx were 
no1 performed m the rcoccIus~on study. the plasmmogen 
levels (obtained before infusion) from the other two sludlcs 
wem a major determinant of thrombolysis with n-PA. An 
Fieure 1. h 
L the 0 005 lcvcl The rate ratio (ratio of patency rates) 
had among the highest values uf all variables investigated 
fTatdc 5). 
Fibrinopen Ict rb, activated pa&l thromboplastin time 
and erythocyte sedimentation rate demonstrated little or no 
relation to patency. 
For rhose polients with a hemnrocrir in the middle rclnpe 
(43 to 47%). the patency rate (80% patent) was considerably 
higher than in either the low heinatocrit subgroup (53% 
patent) or high hematocrit subgroup (63% patent) (Fig. 48). 
Multivariate analysis also showed that the mid-hematocrit 
range was a highly significant independent predictor of 
patency. 
Liver and kidney function. Blood urea and crealinine 
levels both demonstrated a trend toward reduced coronary 
patency levels in the highest tertial, although this failed to 
reach statistical significnnce (Table 5). Nevertheless. this 
was consistent with a pattern of reduced renal function being 
associated with greater chance for achieving patency. Nei- 
ther blood urea nor creatinine would be expected io have 
changed appreciably in the first 6 h as a result of a reduction 
in cardiac output after the acute event. 
Serum ulksline phospkatose. although unavailable in 123 
patients, did demonstrate astatistically sinniiicanl trend with 
patency for values ~32% of the locain&&al limit (patency 
rate also 82%) (Fig. 4C). Similarly. in those patients with an 
alkaline phosphatase value <62% of the lo&l normal limit, 
the patency rate was depressed (56% patency). 
hlultivariatu snnlysis. The variables reported in Tables I 
through 5 were syslemalically evaluated in a multivariate 
logistic regression analysis. In addition, it was necessary to 
establish whether there were systematic differences in the 
outcome of the three separate trials that constituted the data 
base for this report. The findings were negative. Neither age. 
sex. ECG derived variables nor results of the c~rmrary 
an&gram WR stattstically stgnificanl multtvariate predic- 
tors of coronary patency status. 
However. hcmatocrit. sew,? alkaline phospbatese and 
plasminogcn, variables already identified in the univariate 
analysis, did prove to be independent predictors of outcome. 
The cutoff values for these variables as well as the resulting 
odds ratios arc summarized in Table 6. Either a low or a high 
value of hematocrit was awciatrd with a less favorahte 
outcome in contrast with B normal VBIUC of hsmatocrit (41 to 
47%). Plasminu~en levels below 90% were independently In con+,w! :n wr xnes. an infravenoui idwion wit5 
associated with a much lew favomhle outcome. High ICY& ,i,w!cd ,mmcd,atety. and rhe firrt angmgram wai performed 
. . . __^ :_ ui ai’naiinc piw3pmi~arr ILIL ~&+io&x;ly aisaiiz:c_’ -i:t; 11 zi:: :T:c: :te T!Z:: of !nfes:eo. a,,,,3c WC rilnnd nn 
a more favorable outcome. relation hetrreen the time delay and the patency rav. Ihc 
The odds ratio for each variable reponed m TaKe 6 diRerenre in 1mir.g i3 probably nor a major factor m patency 
should be interpreted a3 the relative chance of oc’:uGon in (noi to hc ;qwted with prcrervation of myucardiat function) 
relation to the ab3ence of the 3pecified condition For However. it !F oonible that !he two p&n: group? arc not 
example. patients with a normal hematscrit value (4) to comparable because Tendera et al. (6) would hav: cxclcded 
47%) have one-third the chance of hn occlusion compared :hwe Qaneniri who showed signs of spontaneous reperfu- 
with patients with either a lower or a higher hematocnt wn. and Me loformation IS avai:able conrrmmg rhc I!kli- 
vdue. For a level of alkatine oharohatase >82% of thr lxal hood of wm1awou3 Ivds in oroxzmal ve33eI or lcb anicrior 
reference value, the oJds ra;io was 0 29 for an OCCIUFIO~. deicend,;g coronary .anery’ dwzase, or both. Also. the 
and for $wzinogen >% the oddr r&o wa> 0 41 clinical and ECG inclusion cnteria ‘here more WXI nn ihe 
European cooperative 3tudier. Moreover, bz;ause of the 
Consideting the number of compansons exammed in rhn 
Discussion 
report. there is a rink that one or m&e positme findings could 
occur purely by chance. For example. if p= 0.005 is ret as 
the limo of statistical significance, the chance of obtamiag 
one or more significant findings in 48 comparisons ic about 
one in five. when in fact no real difference exi>t3. This caveat 
applies to aher studies as well and underscores the need for 
independent contimntian. 
tar W-PA) am generally lower than those reported for 
introcoronary streptokinaae (5). Because we had decided to 
institute thrombolytic therapy as quickly XT possible. a 
preinfusion angiogram was not performed. Thus. stringent 
Csroaary patency ratea. The patency rates reported here 
for intravenous recombinant tissue-woe olasc!noeen aiuva- 
criteria (see Methods) were applied in assessing infarcr- 
related vessel patency. This may have resulted in classifying 
subjective nature of scoring coronary zngiograms. the angm- 
graphic assessment panel operated idependent!y of the 
climcal mvestigaronand without knowledge ofrhe history of 
the QaW”, nil the treat”e”L 
The fact that the angiogram provided no valid baaw for 
srnt!ficanon also undermine3 the potential utdity of Ihe ECC 
in this regard. Therefore. the finding that the ECG mfarcl 
iocawn and estimae of it3 size have II ‘::!e corxkdion wi:h 
patency IF a co”3l3te”t finding. 
Rote of intrmencw nitrsta. The use of intravenous ni- 
tratc~ could he expected to ~ncreace coronary tlow. deliver a 
greater quaniity of n-PA in the vicmity of !he infarct-related 
&I and thereby improve chances for achieving patency 
Indeed. the patency rilte in 72 Qatlenls who recewcd intra- 
venous nitrate3 in the 6 h period before allocation war 9 
percent;;e paints higher than in the 171 who did not rcccw 
intravenous nitrates, although the 95% confidence interval of 
the raw ratio mctudes umty. RerWop et al. (7; weportld a 
as occluded &me vessels that might otherwise have been 
assessed as patent had the meinfusion anniomam been 
available to &se33 the change iA patency status. On the other 
hand. it can be estimated that about 20% of our patients 
would have bad patent vessels at the start of rhe inf%isn. 
Because these patients were not identifiable m this study 
(and are thus insluded in the analysiG. their inclusion would 
tend to result in a higher patency rate than rhat If rtudies m 
which such patient3 were excluded at the outre:. 
If the location of the infarct-related vessel had an impor- 
tant bearing on the chance of achicvmg patency. this could 
form a basis for stratifying patients for treatment. Unfortu- 
nately. we are uoable to confirm reporn ,6) regardmg the 
mox favorable outcome for proximnl vewel d1aez.e or 
involvement of the left anterior descending coronary artery 
Coronsry collateral ~e~3el3 were 3een m 10% of me patientr. 
but had no bearmg on the outcorm. 
intracoronary administnttiun ofurokma~c and ~eptokmarc. 
coronary arterioyraphy was performed before the mfwon 
larger ddference IIg percentage point31 in favor of mtrater in 
a total wizs of 43 pa!icnts: this also was not Ftatictically 
Ggnificant. If tbc data from !he two studtes are pooled. the 
recult :; 4 i2 pcc~enlage point diffexnce in patency WC m 
favor of u~ng a thrombotytlc agent with intravcnou> ni- 
trate>. which is ~tatislically sigmticant (p - 0.051. Although 
there ~ppearr to be a consistem trend in favor of intrwcnoux 
nitrates. awe do not conclude that the care ii prawn. A 
potential gain of 12% In patent veSel( at rebativcly 11111: 
addmonai co3t cannot be Ignored and should be further 
mvestlgated. 
Hematocrit. The ohservat:on that an intermediate wlue 
of hcmatocrit was assocratcd with greater patency rhan WI 
either a lower or hi&r v&r wa\ unarticpatcd. Hemarocnt 
I\ one of the mo~f easily determined laboratory tests and 13 
not subject to whimsical calibration ofcomplicated blachem- 
icol equipment: of all Ihe hemostatic and biachemtcal iestc. 
it win moot conrirtently performed (availabtc in 228 of 243 
parxn~s) Therefore. one finds it dificulr to divmrs hc 
findingas ri meawrcmcn~ or ~latic~~cal anomaly. lfwe accept 
the re\ult at face value. two mechaonms are possibly 
mvohed. A high hematocrd value would rewll III increased 
blood viscosily. with a relatively greater ddlicolty in deliv- 
wine n-PA lo ,he vicinitv of a thrombus in an occluded or 
severely stenosed arlery:.for example. on increase in hema- 
tocri, from 4OC +o SO% would mcrease viscosity by B factor 
of from 1.4 to 12. depending on shear rate (8). Why a low 
hemalncrit valw would also be asocialed with a relatively 
lower patency rate is no, obvious. For a iarge hematocrit 
difference (for example. 40% versus HI%). there could be an 
imponant difference in the plasma volume in which n-PA is 
distriboted and therefore in the plasma concentration of 
n-PA Ia factor of 1.5 for a hematocrit of 60% versus 40%). 
Earlier studies (9) on tbc ret&on between bemalocrit and 
acute myocardial infarction have shown tha, pafients wilh a 
more severe infarction also have a lower hematocri, level. 
although this usuillly becomes manifest over several days 
rather than within hours of the acute event. These possible 
cxplanalions remain speculalive, and the result itself needs 
:o he co+!mwI in other aludics. 
Alkaline phosphatase. Alkaline phosphalasc is produced 
by many tissues (liver. inlealine, bone and placenta) and is 
excreled in bile. In ,he absence of osteal disease and 
pregoancy. an elevated ~enm alkaline phosphatase level 
generally reflects impaired hepatic excretory function as is 
seen in hepatitis, cirrhosis and biliary tract obstruction. 
Because n-PA is metahalized in ,he liver (half-life in the 
circuldlion of approxima,ely 7 min). compromised liver 
function could indirectly rerult in both higher levels of rt-PA 
in ,he blood and a longer period of activity, and therefore 
greater effectivity in terms of coronary recanalization. Bc- 
cause a history or clinical signs of hepatic disease were 
exclusion criteria for this study, any biochemical evidence of 
such disease mu, ,o hc inarprctcd aa a subclinical manifes- 
tation. The implicalion is lha, to achieve an optimal dosage, 
this factor may have ,o be taken info accoun,. 
Plasminogen. The fait tba, a high staning value for 
plasminogen is strongly associated with rt-PA-induced 
lhrombolysis is an expected finding consiant with the 
mechanrim of action of n-PA. 
Conclusions. An analysis of the rewlts of the firs, lhree 
studies (l-3) of the European Cooperative Study group oc 
rt-PA has been undertaken 10 iden:::) those :kii.z,s as,oci- 
ated with coronary angiographic palcncy. The aoalysis fo- 
cused pnncipally on rhose facron tha, can be assessed early 
after admwon and before the stat of infusion. W,thin the 
framework ofthe inclusion and exclusion crilcriaofthc three 
independent biochemical prediclors of outcome: hematocri, 
in the range of 43 10 47%. plasminogen of ~90% and alkaline 
phosphatase u: 882% of the lvd normal limit. Neverthe- 
less. the combined predictive accuracy of these measure- 
ments is no, high enough. in our opinion, for one to be &ble 
to select with sufficient certainty lhose patients who will or 
will not benefit from treatment with rt-PA. In particular. 
attempts to manipulate these factors in a direction favoring 
patency are unwarranted, although this may be a fruitful area 
for further research. The role of intravenous nitroRlycerin 
remains ambiguous, and further studies are war&,~d be- 
cause the evidence suggests that the use of intravenous 
&ales is associated with higher patency ra,es. 
Providing that the inclusion and exclusion criteria main- 
tained in the first three European cooperative studies are 
satisfied. a 40 mg infusion of R-PA over 90 min can be 
administered successfully in the majority of patients. An 
overall palency rate of 65% abler 90 min of infusion can be 
LXpCClCd. 
sludiea. nenherrhe size non the location ofthe i&arc, norfbe 
site of Lhe slenolic or occluded segments provides a practical 
basis for stratifying patients ill terms of likely outcome. 
